CCL2 and osteosarcoma: At one month following tumor-clearing CAR T cell therapy, the aggressive osteosarcoma model exhibited persistently elevated serum levels of CCL11, CCL2 and BAFF compared to tumor-bearing, mock T cell-treated control mice (Fig S1A–S1B).